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Abstract
 Diseases such as hypertrophic cardiomyopathy (HCM) canBackground:
lead to severe outcomes including sudden death. The generation of human
induced pluripotent stem cell (hiPSC) reporter lines can be useful for
disease modelling and drug screening by providing physiologically relevant 
 models of disease. The   locus is cited as a safe harbour thatin vitro AAVS1
is permissive for stable transgene expression, and hence is favoured for
creating gene targeted reporter lines.
: We generated hiPSC reporters using a plasmid-basedMethods
CRISPR/Cas9 nickase strategy. The first intron of  , the PPP1R12C AAVS1
locus, was targeted with constructs expressing a genetically encoded
calcium indicator (R-GECO1.0) or HOXA9-T2A-mScarlet reporter under the
control of a pCAG or inducible pTRE promoter, respectively. Transgene
expression was compared between clones before, during and/or after
directed differentiation to mesodermal lineages.
: Successful targeting to   was confirmed by PCR andResults AAVS1
sequencing. Of 24 hiPSC clones targeted with pCAG-R-GECO1.0, only 20
expressed the transgene and in these, the percentage of positive cells
ranged from 0% to 99.5%. Differentiation of a subset of clones produced
cardiomyocytes, wherein the percentage of cells positive for R-GECO1.0
ranged from 2.1% to 93.1%. In the highest expressing R-GECO1.0 clones,
transgene silencing occurred during cardiomyocyte differentiation causing
a decrease in expression from 98.93% to 1.3%. In HOXA9-T2A-mScarlet
hiPSC reporter lines directed towards mesoderm lineages, doxycycline
induced a peak in transgene expression after two days but this reduced by
up to ten-thousand-fold over the next 8-10 days. Nevertheless, for
R-GECO1.0 lines differentiated into cardiomyocytes, transgene expression
was rescued by continuous puromycin drug selection, which allowed the Ca
 responses associated with HCM to be investigated   using singlein vitro
cell analysis.
 Targeted knock-ins to   can be used to create reporterConclusions: AAVS1
lines but variability between clones and transgene silencing requires careful
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 lines but variability between clones and transgene silencing requires careful
attention by researchers seeking robust reporter gene expression.
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Introduction
A key consideration for targeted gene delivery in human 
induced pluripotent stem cells (hiPSCs) is the genomic 
location at which to insert the exogenous DNA sequence to 
maximise transgene expression and limit disruption of critical 
endogenous genes and their function. To this end, a number of 
chromosomal locations that are amenable to integration have 
been exploited. These regions of the genome are commonly 
referred to as safe harbour loci, and often share some com-
mon properties such as limited disruption to endogenous genes, 
low proximity to oncogenes and a chromatin structure that 
is not prone to epigenetic silencing1,2.
Examples of previously utilised genomic safe harbour loci 
include the chemokine (C-C motif) receptor 5 (CCR5) gene3,4, 
the human orthologue of the mouse Rosa26 locus (hROSA26)5, 
and a region within intron 2 of the Citrate Lyase Beta-Like 
(CLYBL) gene6.
The AAVS1 locus is an area of chromosome 19 (position 
19q13.42) that has been found to be a common integration site 
for exogenous DNA delivered to cultured cells with adeno-
associated virus (AAV)7,8. Integration into this site is associ-
ated with only limited disruption of endogenous genes. The 
phosphatase 1 regulatory subunit 12C (PPP1R12C) gene codes 
for a protein with a poorly defined function, and its first intron 
is disrupted by integration into the AAVS1 site, with no observed 
deleterious consequences in targeted human pluripotent stem 
cells (hPSCs)2,9. DNA sequences inserted at this location are 
supposedly protected by endogenous insulator regions10. These 
insulators are considered to contribute to maintaining an open 
chromatin conformation at the AAVS1 locus, reducing the 
likelihood of transgene silencing compared to other safe 
harbour loci such as CCR54,11. However, some reports of DNA 
methylation dampening transgene expression in hPSC-derived 
hepatocytes raise questions on whether a ‘perfect’ safe har-
bour locus exists12. Despite this, AAVS1 has remained popular 
for gene targeting13–16.
We sought to utilise CRISPR/Cas9 nickase to target the 
AAVS1 locus in hiPSCs and introduce a genetically encoded 
calcium indicator, R-GECO1.0, to enable live Ca2+ imaging 
in hiPSC-derived cardiomyocytes (hiPSC-CMs)17,18. This was 
performed in genome engineered isogenic hiPSC lines we pre-
viously described to model the condition, hypertrophic cardio-
myopathy (HCM). These included a trio of lines harbouring a 
c.MYH7C9123T mutation19 and a duo harbouring a c.ACTC1G301A 
mutation20.
In addition, CRISPR Cas9 targeting of the AAVS1 locus was 
used to target a doxycycline-inducible HOXA9-T2A-mScarlet 
cassette into hiPSCs with the aim of modulating HOXA9 
during haematopoietic differentiation.
We found that, far from being a safe harbour locus, AAVS1 
integration associated with transgene expression that varied 
between clones and/or was silenced during directed differen-
tiation towards both haematopoietic cells and cardiomyocytes. 
This suggests that silencing at the AAVS1 locus is not limited 
to the endoderm lineage as previously described12. Neverthe-
less, by altering our methods from bulk population analysis to 
single cell confocal laser line scan microscopy, we used the 
hiPSC-CMs expressing R-GECO1.0 to investigate the impact 
of HCM mutations on Ca2+ transients. Abnormalities were 
found in both HCM-associated mutations c.MYH7C9123T and 
c.ACTC1G301A, and this phenotype was successfully rescued 
with drug treatment. This demonstrates an in vitro alternative to 
some aspects of drug testing on animal models of HCM. Finally, 
we conclude that the AAVS1 locus cannot be considered a 
true safe harbour. Researchers seeking to target this locus 
should check clones for transgene expression status both in 
hiPSCs and in differentiated progeny.
Methods
Ethical statement
Informed patient consent was obtained for all patient-derived 
hiPSC samples to be used for research purposes. Isolation and 
use of patient fibroblasts was approved by the Nottingham 
Research Ethics Committee (License 09/H0408/74), and 
sample collections are registered with the UK Clinical Research 
Network under project 8164.
hiPSC culture and differentiation
All cell culture experiments were performed in a type II Bio-
logical Safety Cabinet, and cells were incubated in a humidified 
incubator at 37°C and 5% CO2. hiPSCs were routinely main-
tained in E8 medium on 1:100 Matrigel (Corning #356235) 
coated plastic ware (Nunc). Cells were passaged every three days 
by washing once with Ca2+/ Mg2+-free Phosphate Buffer Saline 
(PBS, Gibco #14190-094), followed by incubation with TrypLE 
for four minutes. Subsequently, hiPSC were resuspended in 
E8 supplemented with 10 μM Y-27632 (ROCKi, Tocris Bio-
science #1254/10) and seeded into new Matrigel-coated flasks at 
approximately 20000 cells/cm2. Medium was changed every day.
hiPSC differentiation to cardiomyocytes was performed as 
previously described19,20. Briefly, culture vessels were seeded 
at approximately 20–40 thousand cells / cm2, followed by a 
Matrigel™ overlay step two days later, supplemented with 
1 ng/ml BMP4 [R&D #314-BP-050]. 16 hours later, medium 
was changed to StemPro™34- Serum Free Medium [SP34, 
Gibco #10639011], supplemented with 8 ng/ml Activin A 
(ActA, LifeTechnologies #PHC9564) and 10 ng/ml BMP4. After 
48 hours medium was changed to RPMI B27 without insulin 
(LifeTechnologies #A1895601), with 10 μM KY0211 (R&D 
#4731) and 10 μM XAV939 (R&D #3748). 48 hours later, medium 
was changed to RPMI B27 (LifeTechnologies #0080085-SA) 
with 10 μM KY0211 and 10 μM XAV939. Thereafter, medium 
was changed every 2–3 days with fresh RPMI B27 until day 15 
of differentiation, when hiPSC-CMs were dissociated using 
collagenase21, re-plated, and kept in RPMI B27 for another 
week until phenotypic assays were performed.
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hiPSC differentiation to haematopoietic cells was performed 
by passaging hiPSCs using Gentle Cell Dissociation Reagent 
(GCDR; Stem Cell Technologies #07174) and Corning cell 
scrapers (Sigma #CLS3008) when colonies had compacted and 
wells were 70–80% confluent. Differentiation was performed 
using STEMdiff™ Haematopoietic Kit according to the sup-
plied protocol (Stem Cell Technologies #05310). Briefly, hiPSCs 
were dissociated as cell aggregates with GCDR for 7–10 minutes 
at room temperature, followed by scraping. Cell aggregates 
(50–200 μm in diameter) were seeded at different ratio densities 
in E8 media. The following day, only wells that contained 
16–40 colonies >50 μm in diameter were selected to con-
tinue with differentiation and media was changed to Media A 
(day 0 of differentiation). On day two, a half Media A change 
was performed. On day three, media was changed to Media B 
and half Media B changes were performed on days five, 
seven and 10. On day 12, suspension cells were harvested for 
downstream analysis.
CRISPR-Cas9 gene targeting of the AAVS1 locus
In order to target the AAVS1 locus in hiPSCs, a targeting 
vector was constructed containing either the CAG-R-GECO1.0-
IRES-Puro cassette17 or the doxycycline-inducible HOXA9-
T2A-mScarlet-CAG-G418 cassette flanked on each side with 
1 kb of homology to the AAVS1 locus22. 1 μg of AAVS1 target-
ing vector was transfected into 1 × 106 hiPSCs, with 500 ng 
of each AAVS1 guide RNA pU6 vector and 1 μg of hCas9 D10A 
nickase plasmid using an Amaxa 4D system (Lonza) accord-
ing to the manufacturer’s instruction. 24 hours after transfec-
tion, the medium was supplemented with 0.3 μg/ml puromycin 
(Life Technologies #A1113802) or 50 μg/ml Geneticin™ 
(Life Technologies #10131027) depending on the drug 
selection cassette for positive selection of clones up to 10 days 
post-transfection. Drug-resistant clones were then isolated using 
0.5 mM EDTA and expanded. Clones were then genotyped 
using polymerase chain reaction (PCR) on genomic DNA using 
Phusion® polymerase (NEB Cat# M0530S) and the primers 
given in Table 1. PCR cycle parameters were 95°C for 
2 minutes, 60–64°C for 30 seconds and 72°C for 60 seconds, 
with a final elongation step of 72°C for 10 minutes.
Immunocytochemistry
Dissociated hPSC-CMs or hPSCs were cultured in vitronectin- 
or MT-coated 96-well plates (CellCarrier, Perkin Elmer 
#6005550), respectively, at approximately 50K cells/cm2 as 
described above. Cells were washed with PBS and fixed in 
4% Paraformaldehyde (PFA, Sigma) at room temperature 
(RT) for 15 minutes. Afterwards, cells were washed in 0.1% 
Tween-20 (Fisher Scientific) in PBS, permeabilized with 0.1% 
Triton-X (Sigma) in PBS for 15 min at RT, and incubated 
with 4% goat serum (Sigma) in PBS (blocking solution) 
for one hour at RT to prevent unspecific antibody binding. 
Subsequently, primary antibody incubation was performed 
overnight at 4°C in blocking solution at the following dilutions: 
mouse monoclonal anti-OCT4-1:200 (Santa Cruz Biotechnology 
Cat# sc-5279, RRID:AB_628051), rabbit polyclonal anti-RFP-
1:1000 (Abcam Cat# ab124754, RRID:AB_10971665), mouse 
monoclonal anti-α-actinin-1:800 (Sigma-Aldrich Cat# A7811, 
RRID:AB_476766). Thereafter, samples were washed three 
times with 0.1% Tween-20 in PBS and incubated with Alexa 
Fluor secondary antibodies (Life Technologies) in block-
ing solution for one hour at RT. Afterwards, cells were washed 
with 0.1% Tween-20 in PBS for 3x five minutes, followed by 
nuclei and/or whole cell counterstaining with 0.5 μg/ml DAPI 
(Sigma #D9542) or Cell Mask (1:10000, Invitrogen #H32721) 
in PBS, respectively, for 30 minutes at RT. Samples were 
subsequently washed and stored at 4°C in PBS until auto-
mated image acquisition was performed in the Operetta™ 
high-content imaging system (PerkinElmer) and analysed using 
Harmony high-content imaging analysis software.
Live imaging mScarlet expression
Live imaging of mScarlet fluorescence in differentiating 
hiPSCs was performed using Operetta™ high-content image 
analysis every two days. All images were taken using a 20x 
objective. Brightfield images were taken using 100 ms expo-
sure time. mScarlet imaging was performed using 400 ms 
exposure and an excitation wavelength of 520–550 nm and 
an emission wavelength of 560–630nm. Data analysis was 
performed using Columbus™ software (PerkinElmer) to identify 
and quantify cell regions expressing mScarlet fluorescence.
Table 1. Primers used for PCR screening of AAVS1 integration.
PCR screen Forward primer sequence  
(5’ → 3’)
Reverse primer sequence (5’ → 3’) Annealing 
temperature
5’ integration screen 
(Outside AAVS1 Left Arm Homology – CAG 
promoter)
TCCCCTCTTCCGATGTTGAG TGGGCTATGAACTAATGACCCCG 64°C
3’ integration screen 
(IRES/Puromycin – Outside AAVS1 Right 
Arm Homology)
AGCGTATTCAACAAGGGGCT ACCCCGAAGAGTGAGTTTGCC 62°C
Biallelic targeting screen (Inside AAVS1 
Left Arm Homology – Inside AAVS1 Right 
Arm Homology)
ATGCCGTCTTCACTCGCTGG GGGGCTTTTCTGTCACCAATCC 64°C
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Gene expression analysis by qPCR
Real-time qPCR reactions were performed using TaqMan® Gene 
Expression Assays (Applied Biosystems) following manufac-
turer’s instructions. Briefly, Taqman® mastermix (#4369016) 
including the HOXA9 probe23 was added to a MicroAmp Fast 
96-well plate (#4346907). Subsequently, cDNA samples (from 
initial 500 ng of reverse-transcribed RNA) were added to the 
plate, which was thereafter sealed with a film (#4311971). 
Amplification was performed in ABI 7500 Real-Time PCR 
system (Applied Biosystems). Cycle conditions were 50°C 
for 2 minutes, 95°C for 10 minutes followed by 40 cycles of 
95°C for 15 seconds and 60°C for 1 minute.). Normalisation 
was performed using the housekeeping gene B2M or PP1A. 
Relative quantification was calculated using the ΔΔCT method24 
in Microsoft Excel.
Confocal analysis and ClampFit identification of abnormal 
Ca2+ transients
hiPSCs were differentiated as previously described19,20 in RPMI 
B27 without phenol red and dissociated on day 15 by colla-
genase treatment. On day 30, hiPSC-CMs were seeded at a 
density of 150,000 cells per well in vitronectin-N coated Mat-
Tek dishes. Intracellular Ca2+ transient measurements were 
made using an LSM 880C confocal microscope (Carl Zeiss) 
in the line-scan mode as previously described25. CMs were 
located using a 40x oil objective and a longitudinal line was 
drawn across a single CM. The R-GECO fluorophore was 
excited with a 561 nm laser at 0.8% power, with a detection 
range of 579 – 639 nm. Line-scan images were taken every 
75 milliseconds, with a pixel dwell time of 4.12 μsec, for a 
total of 4000 cycles resulting in a five minute scan. CMs were 
kept at 37°C and 5% CO2 throughout data acquisition.
Confocal line scan images were analysed in FiJi software, a 
version of ImageJ (National Institute of Health). The aver-
age fluorescence intensity of each line was calculated against 
time to give a confocal line-scan trace. Using the ‘multi 
kymograph’ function, a corresponding kymograph image 
was produced. In order to calculate beat rate and arrhythmic 
events, data was fed into pClamp software (Molecular Devices). 
Baselines were adjusted to account for photobleaching and 
Ca2+ transients were counted and analysed using the ‘event 
detection’ function. Using the event viewer, any Ca2+ tran-
sients that did not return to baseline and gave a ‘double peak’, 
or did not return to at least 75% of the previous Ca2+ transient 
amplitude, were considered ‘abnormal’, as described in 20.
Statistical analysis
All data presented as mean with standard deviation unless 
otherwise stated. Statistical analysis of multiple data sets 
was performed using GraphPad software (version 7.04).
For multiple comparisons between data sets a one-way ANOVA 
with Tukey’s multiple comparison test was chosen. For 
comparing multiple data sets to a single control column, 
one-way ANOVA with Dunnett’s multiple comparison test was 
chosen. Significance tests were based on p-values as follows: 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Results
Knock-in of transgenes into the AAVS1 locus
Our overarching goal was to create two isogenic sets of hiPSC 
lines in order to study Ca2+ handling in the context of in vitro 
models of the disease HCM. One isogenic trio comprised lines 
that were wild-type (MYH7WT/WT), heterozygous (MYH7WT/MUT) 
and homozygous (MYH7MUT/MUT) for the c.MYH7C9123T mutation19. 
The other comprised a pair that were heterozygous 
(ACTC1WT/MUT) and corrected (ACTC1WT/WT) for the c.ACTC1G301A 
mutation20.
The AAVS1 locus, located within the first intron of PPP1R12C 
on chromosome 19 (Figure 1A), is a well characterised safe har-
bour locus2. Using the five lines above, we targeted a cassette 
containing R-GECO1.0 reporter and a puromycin resistance 
cassette, driven by the CAG promoter, into the AAVS1 
locus (Figure 1A)22. This was achieved by using a CRISPR-
Cas9 nickase approach based on two sgRNAs. Nucleofection 
of the HCM-associated hiPSCs with the R-GECO1.0 construct, 
bidirectional sgRNAs and Cas9 D10A nickase plasmids pro-
duced puromycin-resistant clones. PCR-based screening and 
sequencing were used to examine the regions upstream 
(Figure 1B) and downstream (Figure 1C) of the insertion site, 
and hence identify clones that were successfully targeted in 
one or both alleles (Figure 2B, C).
In addition, the MYH7WT/WT hiPSC line was used to introduce 
a HOXA9-T2A-mScarlet cassette driven by a doxycycline- 
inducible pTRE promoter into the AAVS1 locus using the 
same CRISPR-Cas9 nickase approach (Figure 1A). Both 5’ 
(Figure 1D) and 3’ integration (Figure 1E) to AAVS1 was 
assessed using the same PCR genotyping approach on genomic 
DNA to identify successfully targeted clones.
Variability in transgene expression at the AAVS1 locus
In order to quantify R-GECO1.0 expression across the tar-
geted clones, high content image analysis was used on hiPSCs 
that were dual-stained with anti-OCT4 for pluripotency and 
anti-RFP antibody, which identifies R-GECO1.0 (Figure 2A)22.
Transgene expression varied widely both between, and within, 
cell lines. The percentage of cells expressing R-GECO1.0 
in AAVS1-targeted ACTC1WT/WT hiPSC clones ranged from 
a maximum of 96.4% to a minimum of 32.6% (Figure 2A), 
and in isogenic mutant ACTC1WT/MUT hiPSC clones from 49.4% 
to 0%. Selected clones for the isogenic trio of MYH7WT/WT, 
MYH7WT/MUT and MYH7MUT/MUT hiPSCs showed comparatively 
high R-GECO1.0 expression exceeding 73.09% in all cases, an 
important requirement for a more faithful comparison between 
lines (Figure 2A).
This variability could not be explained by the incidence of bial-
lelic targeting, as determined by PCR screening. Both alle-
les were targeted in ACTC1WT/WT clones three and six, which 
exhibited high R-GECO1.0 expression as hiPSCs of 91.1% 
and 85.4%, respectively. This was comparable with the 
95.6% and 96.4% expression observed in the monoallelically 
targeted clones 11 and 12, respectively (Figure 2A and 2B). 
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Figure 1. Generation of AAVS1-targeted hiPSC clones in an isogenic MYH7 C9123T background and an isogenic ACTC1 G301A 
background. (A) Schematic illustrating the chromosomal location of the AAVS1 safe harbour locus. This site was targeted using two sgRNAs 
in a CRISPR Cas9 nickase strategy. PAM site #1 was silently mutated (G→C) in the targeting construct to prevent it being cut by Cas9 
nuclease during targeting. The inserted cassette consists of R-GECO1.0 IRES-Puromycin driven by the CAG promoter. This is flanked on 
each side by 1 kb of homology to the AAVS1 locus. In (B) and (C) confirmatory 5’ and 3’ targeting PCR screen is shown using genomic DNA 
isolated from the MYH7 C9123T RGECO1.0 isogenic trio (left) and the ACTC1 G301A RGECO duo (right) hiPSCs. Correct 5’ targeting is 
indicated with a 1221bp product, with sequencing confirming the fidelity of the junction between the AAVS1 left arm homology and the start 
of the CAG promoter. Correct 3’ targeting is indicated with an 1186bp product, with sequencing confirming the fidelity of the junction between 
the puromycin-SV40 pA sequence and the AAVS1 right arm homology. (D, E) Confirmatory PCR and sequencing of hiPSC clones to check 5’ 
and 3’ targeting of the AAVS1 locus with the HOXA9-T2A-mScarlet cassette.
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Figure 2. Immunocytochemistry-based screening of AAVS1-targeted clones showing differential expression of R-GECO1.0 between 
and within cell lines. (A) AAVS1 targeted hiPSC clones dual-stained for OCT4 (green) and R-GECO (red) to find the highest R-GECO-
expressing clone within the five cell line genotypes. High content image analysis identified that ACTC1WT/WT clone 3 had the highest 
percentage of pluripotent (94.53% OCT4+) and R-GECO (91.06% ±1.73%) hiPSCs. ACTC1WT/MUT clone 12 clone had the highest expression 
of R-GECO (49.37% ±1.33%). Mean ±SD, n = 3 wells. One-way ANOVA with Dunnett’s multiple comparison test, * p ≤ 0.0259; ** p < 0.0045; 
**** p < 0.0001. Scale bars = 50 µm. (B) Biallelic targeting PCR screen on isolated gDNA from targeted ACTC1WT/WT hiPSC clones showing 
homozygous clones failure to generate the 517bp PCR product. (C) Biallelic targeting PCR screen showing that all ACTC1WT/MUT clones tested 
resulted in a 517bp product and were therefore heterozygous for AAVS1 targeting. L – 1kb ladder; N – no template control; U – untargeted 
cell line; + - AAVS1 biallelic positive control. (D) Screening MYH7MUT/MUT clones using immunocytochemistry on differentiated hiPSC-CMs 
reveals a significant increase in R-GECO1.0 expression in the MYH7MUT/MUT Hom 2 clone. Mean ±SD, n = 3 technical replicates. One-way 
ANOVA with Tukey’s multiple comparison test, ** p ≤ 0.006; **** p < 0.0001. Scale bars = 50 µm.
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Variability between clones was also seen upon differentiation, 
with a MYH7MUT/MUT Hom 2 clone showing 93.1% R-GECO1.0 
expression as hiPSC-CMs, significantly greater than the 
2.1% expression observed in the MYH7MUT/MUT Hom 3 clone 
(**** p = < 0.0001) (Figure 2D).
Taken together, these results highlight that expression levels 
of transgenes seen in hiPSCs can vary significantly between 
AAVS1-targeted clones, which continued to be observed upon 
differentiation. Importantly, the level of variability could 
not be predicted and needed to be tested empirically.
Transgene silencing upon mesoderm differentiation
Three AAVS1-targeted clones of each c.MYH7C9123T genotype 
were identified with greater than 98.3% R-GECO1.0 expres-
sion as hiPSCs (Figure 3A and 3C)22. However, upon differen-
tiation to cardiomyocytes, R-GECO1.0 expression significantly 
reduced in the biallelically targeted MYH7WT/WT clone 
(** p = 0.0015). The monoallelically targeted MYH7WT/MUT 
and MYH7MUT/MUT clones experienced considerable silenc-
ing of R-GECO1.0 expression upon differentiation, with only 
13.03% of MYH7WT/MUT hiPSC-CMs and 1.33% of MYH7MUT/MUT 
hiPSC-CMs expressing R-GECO1.0 (**** p < 0.0001) 
(Figure 3A–C). Nevertheless, to enhance the utility of these 
lines, particularly the low expressing MYH7MUT/MUT clone, puro-
mycin enrichment of the hiPSCs over three passages was used 
to significantly increase the number of R-GECO1.0 expressing 
hiPSC-CMs from 1.3% to 18.9% (*** p = 0.0003) (Figure 3D). 
These results show that high transgene expression from 
the AAVS1 locus as hiPSCs is not a guarantee of continued 
high expression upon differentiation, and points towards 
some extent of silencing upon cardiac differentiation.
Next, we sought to investigate the time at which silencing 
occurs during differentiation. To do this, we used the AAVS1-
targeted doxycycline-inducible HOXA9-T2A-mScarlet line 
and differentiated the hiPSCs towards either cardiomyocyte 
or haematopoietic fate. As expected, the addition of 1 μg/ml 
doxycycline every 48 hours induced expression of HOXA9 
and mScarlet during directed cardiac and haematopoi-
etic differentiation. qRT-PCR analysis of HOXA9 expression 
showed an increase of 22738-fold higher expression com-
pared to untargeted hiPSC control on day 0 of cardiomyocyte 
differentiation (Figure 4A)22. However, HOXA9 expres-
sion decreased thereafter so that by day 10, expression levels 
were only 175-fold greater than untargeted hiPSC control. 
Similarly, qRT-PCR analysis during haematopoietic differen-
tiation revealed peak expression of HOXA9 occurring on day 
two, with 45666-fold greater expression than untargeted hiPSC 
control, decreasing thereafter to 64-fold expression on day 12 
(Figure 4D). These results were mirrored at the protein level, 
where early peak expression of mScarlet fluorescence occurred 
on day 0 of cardiomyocyte differentiation (Figure 4B and 4C) 
and on day two of haematopoietic differentiation (Figure 4E 
and 4F), decreasing at later timepoints of differentiation.
For the haematopoietic differentiation, expression of the key 
mesoderm markers MIXL1 and Brachyury peaked on day two 
(Figure 4G and 4H). This suggests that silencing of the AAVS1 
locus can occur immediately after mesoderm patterning. As a 
whole, these results show a progressive silencing of transgene 
expression as mesoderm differentiation progresses.
AAVS1-targeted R-GECO1.0 expressing clones as a tool 
for in vitro disease modelling and drug screening
Despite some obstacles due to unanticipated AAVS1 silencing, 
isogenic R-GECO1.0 expressing clones in genetic backgrounds 
associated with HCM were successfully generated and used to 
image Ca2+ transients using confocal laser line scan microscopy. 
As this technique involves assaying single cells, even poorly 
expressing clones were useful. By monitoring the fluctuation 
of R-GECO1.0 fluorescence over time, Ca2+ transient traces 
could be generated for each line (Figure 5A–C and 5E–F)22. 
For both the c.MYH7C9123T and c.ACTC1G301A mutations, 
increasing mutation load resulted in an increased incidence of 
abnormal Ca2+ transient events. MYH7WT/WT hiPSC-CMs only 
presented 1.1% aberrant Ca2+ transient events, increasing to 
4.33% in MYH7WT/MUT hiPSC-CMs, and further increasing to 
11.2% in MYH7MUT/MUT hiPSC-CMs (p < 0.0001) (Figure 5D). 
This represented a ten-fold increase in the occurrence of 
aberrant Ca2+ transients in the homozygous mutant compared to 
isogenic wild-type control. Likewise, 15.65% of Ca2+ transients 
in ACTC1WT/MUT hiPSC-CMs were calculated as being aber-
rant, compared to 6.7% (±0.6%) in ACTC1WT/WT isogenic control 
hiPSC-CMs (p = 0.0118) (Figure 5G). This demonstrated 
the utility of the AAVS1-targeted R-GECO1.0 cell lines for 
in vitro disease modelling and phenotyping as a credible 
alternative to the use of animal models.
We then attempted to rescue the aberrant Ca2+ transient phe-
notype in our HCM models with the use of a combination 
treatment of ranolazine, a late sodium channel blocker, and 
dantrolene, a ryanodine receptor antagonist. In combination 
at 10 μM with 24 hours incubation, these two drugs significantly 
reduced the frequency of aberrant Ca2+ transient events in 
MYH7 mutant hiPSC-CMs. In MYH7WT/MUT hiPSC-CMs 
aberrant Ca2+ transient event frequency was reduced from 
6.32% (±3.4%) in vehicle control to 2.18% (±1.9%) with drug 
treatment (p = 0.0068) (Figure 5H–I).
These results show that abnormalities in Ca2+ transients caused 
by the sarcomeric mutations c.MYH7C9123T or c.ACTC1G301A can 
be identified with AAVS1-targeted R-GECO1.0 expression, 
and this phenotype can be subsequently rescued with targeted 
pharmacological intervention aimed at reducing intracellular 
Na+ and Ca2+.
Discussion
Precise integration of exogenous DNA into the genome is often 
performed by targeting a genomic ‘safe harbour’ locus that can 
tolerate gene insertion with few deleterious effects and limited 
transgene silencing. The AAVS1 locus is a popular choice for 
targeted knock in of exogenous DNA15,16. This region of the 
genome is claimed to facilitate robust and persistent transgene 
expression11, aided by flanking insulator regions10. Here, 
we show variable success targeting the AAVS1 locus with 
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Figure 3. Changes in transgene expression during differentiation and antibiotic selection. (A) Immunocytochemistry using an anti-RFP 
antibody to detect R-GECO1.0 expression shows a reduction in signal in MYH7WT/MUT 8 and MYH7MUT/MUT 15 cell lines upon differentiation 
from hiPSCs to hiPSC-CMs. Mean ±SD, n = 3 technical replicates. One-way ANOVA with Sidak’s multiple comparison test, ** p = 0.0015; 
**** p ≤ 0.0001. (B) Percentage purity data for cardiomyocytes determined by alpha-actinin staining (red), for R-GECO1.0 by RFP staining 
(green). Mean ±SD, n = 3 technical replicates. One-way ANOVA with Sidak’s multiple comparison test, **** p ≤ 0.0001. (C) Targeted hiPSC 
lines show variations in expression of R-GECO1.0 protein upon differentiation. hiPSC lines, identified by OCT4 staining (green, top row) show 
high R-GECO1.0 expression (red). Upon differentiation to cardiomyocytes, identified by α-actinin staining (red, bottom row), MYH7WT/MUT 
8 and MYH7MUT/MUT 15 hiPSC-CMs show lower R-GECO1.0 expression (green). Scale bars = 50 µm. (D) R-GECO1.0 expression in MYH7MUT/MUT 
15 cardiomyocytes is significantly improved with three passages of hiPSC cell culture in 0.3 µg/ml puromycin and differentiation carried out 
in media supplemented with puromycin. Mean ±SD, n = 3 technical replicates. Unpaired t-test, *** p = 0.0003.
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Figure 4. Differentiation towards cardiomyocytes or haematopoietic cells results in silencing of AAVS1-targeted transgene after 
mesoderm induction. (A) qRT-PCR performed on hiPSCs targeted at the AAVS1 locus with a doxycycline-inducible HOXA9-T2A-mScarlet 
construct undergoing cardiomyocyte differentiation. Relative expression to untargeted hiPSCs. Reduced expression of the transgene is 
observed from day two onwards. (B) Live imaging of AAVS1-targeted hiPSCs undergoing cardiomyocyte differentiation at different timepoints. 
mScarlet expression peaks on day 0 and reduces throughout the differentiation, despite repeated doxycycline treatment. Scale bars = 50 µm. 
(C) Quantification of mScarlet expression using high content image analysis at different timepoints during cardiomyocyte differentiation. 
(D) qRT-PCR performed on hiPSCs targeted at the AAVS1 locus with a doxycycline-inducible HOXA9-T2A-mScarlet construct undergoing 
haematopoietic differentiation. Relative expression to untargeted hiPSCs. Reduced expression of the transgene is observed from day four 
onwards. (E) Live imaging of AAVS1-targeted hiPSCs undergoing haematopoietic differentiation at different timepoints. Scale bars = 50 µm. 
(F) Quantification of mScarlet expression using high content image analysis shows peak expression on day two and reduced expression 
thereafter. Mean ±SD, n = 2 differentiations. One-way ANOVA with Dunnett’s multiple comparison test, ** p = 0.0036; **** p ≤ 0.0001. (G, H) 
The mesoderm markers MIXL1 and Brachyury (T) show peak expression at day two of haematopoietic differentiation.
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Figure 5. Functional application of AAVS1-targeted R-GECO1.0 expressing clones for in vitro disease modelling of HCM and 
phenotypic rescue with drug treatment. (A–C) Representative 25-second confocal laser line scan traces and kymographs for isogenic trio of 
c.MYH7C9123T R-GECO1.0 expressing hiPSC-CMs at day 30. Abnormal Ca2+ transient events (red arrows) increase in frequency with mutation 
load. (D) Ca2+ transient event detection and quantification showing percentage of Ca2+ transients deemed abnormal. Data presented as 
mean ±SD, n = 6 scans across three differentiations. Kruskal-Wallis test with Dunn’s multiple comparison test; ** p = 0.0018, **** p < 0.0001. 
(E–F) Representative 25-second confocal laser line scan traces and kymographs for isogenic pair of c.ACTC1G301A R-GECO1.0 expressing 
hiPSC-CMs at day 30. Abnormal Ca2+ transient events (red arrows) increase in frequency with mutation load. (G) Box-plot showing % of 
total Ca2+ transient events detected deemed abnormal by event detection software. Data presented as mean ±SD, n = 5 scans from three 
differentiations. Unpaired t-test; * p = 0.0118. (H–L) Representative line scans and event detection quantification showing a reduction in 
abnormal Ca2+ transient events upon treatment with 10 µM ranolazine and 10 µM dantrolene compared to 0.1% DMSO vehicle control. 
Data presented as mean ±SD, n > 4 cells across minimum of two differentiations. Kruskal-Wallis test with Dunn’s multiple comparison test; 
** p = 0.0068.
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the genetically encoded calcium indicator R-GECO1.0 or a 
doxycycline-inducible HOXA9-T2A-mScarlet cassette using a 
CRISPR Cas9 nickase approach.
Variability in R-GECO1.0 expression between AAVS1-targeted 
clones as hiPSCs was observed, highlighting the importance 
of thorough screening of clones. Unsurprisingly, clones that 
had undergone biallelic targeting retained high R-GECO1.0 
expression as hiPSCs, yet monoallelically targeted clones ranged 
from high expression to significantly reduced R-GECO1.0 
expression. These incidences of low expression as hiPSCs 
may be due to clone-specific silencing, or some clones favour-
ing expression from the untargeted allele. It has been shown 
that some genes within cells favour monoallelic expression26. 
Indeed, our own studies using an antibody for the 
c.ACTC1G301A mutation have shown that cells heterozygous 
for the mutation only express mutant protein in ~50% of the 
population20. These results highlight the heterogeneity that can 
exist between clones once they have been generated.
Even with the identification of AAVS1-targeted clones that 
exhibited robust R-GECO1.0 expression, there were instances 
of silencing upon differentiation to hiPSC-CMs. Transgene 
silencing at the AAVS1 locus has previously been shown upon 
differentiation towards hepatocyte-like cells, with de novo 
methylation of the locus found to be responsible12. However, 
the aforementioned report claims that this silencing effect is 
restricted to endoderm differentiations. With the use of the 
AAVS1-targeted HOXA9-T2A-mScarlet cell line, we show 
that in two mesoderm-specific differentiations towards car-
diomyocytes and haematopoietic cells, silencing of expression 
occurs immediately after mesoderm specification and peak 
expression of MIXL1 and Brachyury. We therefore postulate 
that AAVS1-mediated silencing, likely as a result of de novo 
methylation, can occur upon differentiation to various germ 
layers, and therefore AAVS1 cannot be considered a true safe 
harbour locus.
The choice of promoter may also play a role in AAVS1-mediated 
silencing, as a previous report has shown AAVS1 silencing 
of eGFP expression when using the EF1a promoter that was 
overcome with the use of the stronger CAG promoter27. This 
influenced our decision to opt for the CAG promoter over the 
EF1a promoter in our constructs. Indeed, the CAG promoter 
appears to exhibit some insulation from methylation of 
transgenes at the AAVS1 locus12.
When attempting to express two separate transgenes from 
the same cassette at the AAVS1 locus, the choice of peptide 
cleavage sequence is also important. We observed inefficient 
peptide cleavage when using the P2A sequence, as deter-
mined by Western Blot (see Extended data)22. This informed our 
choice of using the T2A or IRES sequences for translation of 
multicistronic cassettes in subsequent targeting constructs. It has 
been claimed that the P2A cleavage sequence is the most effi-
cient self-cleaving peptide, followed by T2A and E2A, when 
used to cleave a bicistronic vector in three different human 
cell lines, including HeLa28. We cannot reconcile this with our 
data, as co-expression of multicistronic cassette elements 
from the AAVS1 locus in hiPSCs has been achieved using the 
IRES and T2A sequence, but not the P2A sequence.
Depending on the application of the targeted cell lines, 
some AAVS1-mediated silencing can be tolerated. For the 
R-GECO1.0 expressing lines, maintaining puromycin selec-
tion and using a single cell confocal laser line scan assay to 
study Ca2+ transients meant that abnormalities in Ca2+ handling 
could be identified in cell lines harbouring the c.MYH7C9123T or 
c.ACTC1G301A mutations. This represents an in vitro model of 
HCM that can offer an alternative to the use of animal models. 
Furthermore, this phenotype could be rescued with combination 
treatment with dantrolene and ranolazine19,20. However, 
the aim with the doxycycline-inducible HOXA9-T2A-mScarlet 
cell line was to modulate HOXA9 expression at different time-
points throughout haematopoietic differentiation. Clearly, the 
clone described herein is not suitable for this task.
In conclusion, one must carefully select AAVS1-targeted 
clones depending on their application due to the risk of trans-
gene silencing upon differentiation. Other potential safe har-
bour loci, such as CLYBL, have been claimed to deliver 
five- to ten-fold higher fluorescent transgene expression than 
AAVS16. However, as silencing cannot be predicted, multiple 
clones must be thoroughly checked for expression level and 
chosen according to their application. Our results dispute the 
claims of robust and persistent transgene expression from 
AAVS111, and complements reports that show silencing at AAVS1 
upon differentiation to endoderm lineage12, by showing similar 
silencing upon mesoderm differentiation.
Data availability
Underlying data
FigShare: Variable expression and silencing of CRISPR-
Cas9 targeted transgenes identifies the AAVS1 locus as not 
an entirely safe harbour. https://doi.org/10.6084/m9.figshare.
c.4573316.v222
This project contains the following underlying data:
-    Figure 1 – data (raw PCR integration gel images in TIF 
format; and sequencing chromatograms underlying 
Figure 1 as AB1 files)
-    Figure 2 – data (raw immunocytochemistry images 
in PNG format; PCR gel images in TIF and PNG for-
mat; and XLS files containing immunocytochemistry 
expression quantification data underlying Figure 2)
-    Figure 3 – data (raw immunocytochemistry images 
in PNG format; and XLS files containing expression 
quantification data underlying Figure 3)
-    Figure 4 – data (raw live imaging images in PNG for-
mat; XLS files containing qPCR data underlying 
Figure 4)
-    Figure 4 data – Raw qPCR data (XLS files containing 
raw qPCR data)
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-    Figure 5 – data (kymographs in PNG format; XLS files 
containing raw confocal laser line scan data underlying 
Figure 5)
Extended data
FigShare: Variable expression and silencing of CRISPR-
Cas9 targeted transgenes identifies the AAVS1 locus as not an 
entirely safe harbour. https://doi.org/10.6084/m9.figshare.
c.4573316.v222
This project contains the following extended data:
-    Figure 6. Western Blot to show incomplete cleavage 
of multicistronic cassette when using the P2A peptide 
cleavage sequence (TIF image file)
-    Protocol for CRISPR Cas9 knock-in at the AAVS1 locus 
and subsequent screening (a step-by-step procedure 
for performing CRISPR Cas9 knock-in at the AAVS1 
locus of hiPSCs, followed by subsequent screening 
techniques in DOCX format)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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In this paper, the authors aim to investigate the effect of hypertrophic cardiomyopathy associated
mutations   and   on Ca  transients using hiPSCs- derived cardiomyocytes.MYH7C ACTC1
To this end, the authors established hiPSCs reporters by introducing a CAG promotor-controlled calcium
indicator (R-GECO1.0) into the   locus through CRISPR/Cas9 nickase-mediated genome editing.AAVS1
Among 24 clones, 20 were found to successfully express the transgene with variation from about 0 to
99.5%. Upon differentiation to cardiomyocytes, even clones with high expression levels demonstrated
significant silencing of the transgene to 13.03% or 1.33%. By creating also an   targetedAAVS1
doxycycline inducible HOXA9-T2A-mScarlet iPSCs reporter, the authors investigated the silencing over
the time course during mesoderm lineage commitment. It was shown that both mRNA and protein levels
of the transgenes were relatively high on day 2 and abruptly decreased from day 4 during both
cardiomyocyte and hematopoietic differentiation.
Despite the silencing of R-GECO1.0 in the   locus, Ca  live image by confocal laser line scanAAVS1
microscopy at the single cell level detected abnormal Ca  transients in cardiomyocytes derived from
hiPSCs reporters harboring   or  mutation compared to wildtype or isogenic control. InMYH7C ACTC1 s 
addition, this abnormality could be rescued by pharmacological inhibiting intercellular level of Na+ and Ca
.
This study shows that iPSC reporter line is of importance for disease modelling. This study presented an
important issue in  -targeted transgene expression in iPSCs and mesoderm lineage although theAAVS1
mechanisms for the silencing are not clear. The variable expression and silencing in mesoderm
differentiation shown here are in line with previous reports that the AAVS1 is not a true safe harbor for
cells differentiated to hematopoietic cells (e.g. PMID: 31773990) and endoderm (e.g. PMID: 26455413);
and, hence, the findings are not fully novel.
Specific comments:
The authors did not mention why for they compared wild-type ( ), heterozygous (MYH7 MYH7
) and homozygous ( ) for the c.  mutation, but no homozygousMYH7 MYH7
mutant line for  .ACTC1
9123T G301A 2+
2+
2+
2+
WT/WT
WT/MUT MUT/MUT C9123T
G301A
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mutant line for  .ACTC1
 
In Fig 2A, the expression of R-GECO in   clones (1/5 with about 50% cells) wasACTC1
lower than in  clones. Is this chance or due to the mutation?ACTC1
 
In Fig 2A, it would be better to show R-GECO in red and OCT4 in green to retain consistency with
other images.
 
In Fig 3C, immunostaining in the upper images showed R-GECO in red while in the lower ones
R-GECO is stained in green, which is difficult to follow.
 
It is interesting to see that puromycin enrichment of the iPSCs over 3 passages increased
R-GECO1.0 expression in   15, did the author also tried puromycin enrichment in MYH7
?MYH7
 
In the introduction, the authors mention that a doxycycline-inducible HOXA9-T2A-mScarlet
cassette targeted in the   locus of hiPSCs is used for modulating HOXA9 duringAAVS1
hematopoietic differentiation. However, this iPSC reporter is also used for cardiomyocyte
differentiation (Fig 4A). It is unclear whether there is specific reason why this reporter line is used
instead of  -CAG R-GECO iPSCs.AAVS1
 
It is better to present RTqPCR result using a ∆Ct method for Fig. 4 as fold changes are confusing
especially in the context of transgene expression (the biological relevance of fold change is unclear
unless one knows the base line transcript levels before gene activation).
 
In Fig 6 - Western Blot (Extended data), to test the peptide cleavage of P2A and T2A, the authors
state that P2A is less efficient than T2A, as NpHR expression (following a P2A) was barely visible.
The authors should provide positive control to exclude that the antibody for NpHR did not work.
 
Southern blots should be performed to make sure that clones tested in this study were targeted in
the corrected locus, and silencing was not due to random integration.
 
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
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There are two arms to this manuscript. The authors aimed to determine the reliability of introducing a
transgene containing a calcium indicator (R-GECO1.0) or a fluorescent reporter (HOXA9-T2A-mScarlet)
into the AAVS1 locus using CRISPR-Cas9 and then subsequently investigate the effect of mutations in 
 or  on calcium handling.MYH7 ACTC1 
Initial experiments showed that although the AAVS1 could be targeted successfully in 20/24 clones, the
expression of the transgene was highly variable. Furthermore, on differentiation of the more successfully
transfected clones to cardiomyocytes, the transgene was silenced with almost complete removal of
expression of the fluorescent reporter. A similar degree of silencing was observed during haematopoetic
differentiation.
Using the mScarlet reporter the authors investigated the timecourse of downregulation and found that with
both cardiomyocyte and haematopoetic differentiation, increased transgene expression was observed at
day 2 but then decreased substantially over time, at both the mRNA and protein level.
Nevertheless, using puromycin selection, it was possible to isolate single cardiomyocytes expressing the
R-GECO reporter and these were used to show that mutations in both   and   resulted inMYH7 ACTC1 
abnormal calcium transient events which could be corrected in part using ranolazine and dantrolene.
 
This is a valuable piece of work which demonstrates shortfalls in what was expected to be a fairly reliable
transfection protocol and that the AAVS1 locus is not as foolproof a site for transfection as may have been
thought. The addition of the calcium transient measurements is interesting in that it shows that something
can be rescued from such a large body of work, but it does come as rather an afterthought in the
manuscript.
 
I have a few minor comments to aid clarity:
The introduction needs to be expanded somewhat. The paragraph on modulating HOXA9 is very
brief and the rationale needs to be explained. In the results section this appears to be merely a way
of monitoring transgene expression, but the short paragraph in the introduction implies some sort
of mechanistic approach.
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 of mechanistic approach.
 
It is not entirely clear to me what the difference is between the data shown in Fig 2D and 3B apart
from different clones.
 
In the section on HOXA9-T2A targeting it says in results that doxycycline was administered every
48 hours. This is not mentioned in the methods or the extended information. The authors state that
transgene induction decreased after day 2. Was this reduction despite further addition of
doxycycline?
 
In figure 5, the timing on the x axis is given in parts H and I but not in other plots. In some others
there is a bar but this is not explained. Is the scale the same throughout? If so, some comment
should be made as to why the wild type MYH7 cells have a slower beat rate than the ACTC1 wild
type cells. The same formatting should be used on all the graphs.
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